Covid-19 roundup: Novartis treatment comes up short in PhIII; Humanigen expands trial, but draws criticism
A major player trying to adapt an anti-inflammatory for Covid-19 has seen the drug fall flat.
Novartis reported Friday that a Phase III trial evaluating canakinumab in hospitalized Covid-19 cases with pneumonia and cytokine release syndrome did not meet its primary endpoint. The interim analysis showed that the drug did not improve the chance of survival without the need for ventilators compared to the control group.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.